已收录 268921 条政策
 政策提纲
  • 暂无提纲
Formulation and Evaluation of SR Tablets of Anti-diabetic drug Gliclazide
[摘要] Recent advances in Sustained Release Drug delivery System (SRDDS) aim to enhance safety and efficacy of drug molecule by formulating a convenient dosage form for administration and to achieve better patient compliance. This present study showed that the Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. Its classification has been ambiguous, as literature used it as both a first generation and second generation sulfonylurea. Gliclazide was shown to protect human pancreatic beta-cells from hypoglycemia-induced apoptosis. It was shown to have an anti-atherogenic effect (preventing accumulation of fat in arteries) in type II diabetes. Gliclazide is used in the tablet form for antidiabetic effect.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 药学
[关键词] Gliclazide;Sustained release tablet;Pharmacokinetic study;diabetes;GLI;glipizide. [时效性] 
   浏览次数:3      统一登录查看全文      激活码登录查看全文